Fibrosis and structural remodeling of the lung tissue can significantly impair lung function,
often with fatal consequences. The etiology of pulmonary fibrosis (PF) is diverse and …

Stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs)
and adult stem cells (ASCs) are able to repair/replace damaged or degenerative tissues and …

Human amniotic membrane-derived mesenchymal stromal cells (hAMSCs) are easily
obtained in large quantities and free from ethical concerns. Promising therapeutic results for …

Pulmonary fibrosis (PF) is a chronic and relentlessly progressive interstitial lung disease in
which the accumulation of fibroblasts and extracellular matrix (ECM) induces the destruction …

Idiopathic pulmonary fibrosis (IPF) is an interstitial disease of unknown etiology
characterized by progressive pulmonary fibrosis. Pirfenidone and nintedanib are the only …

Amniotic mesenchymal stromal cells (hAMSCs) have unique immunomodulatory properties
demonstrated in vitro and in vivo in various diseases in which the dysregulated immune …

Pulmonary fibrosis (PF) is a chronic, progressive, fibrotic interstitial disease of the lung with
poor prognosis and without effective treatment currently. Data from previous coronavirus …

Mesenchymal stem cells (MSCs) have attracted considerable interest as a promising
approach for cancer treatment due to their ability to undergo tumor-trophic migration. MSCs …

Lung fibrosis is a complex process, with unknown underlying mechanisms, involving various
triggers, diseases and stimuli. Different cell types (epithelial cells, endothelial cells …

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial fibrotic disease that leads to
disability and death within 5 years of diagnosis. Pulmonary fibrosis is a disease with a …